Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health TB Testing Coverage Update | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentOscar HealthPolicy N/A

    Testing for Diagnosis of Active or Latent Tuberculosis

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, indications, and limitations for laboratory and diagnostic testing to detect active tuberculosis (TB) disease and latent TB infection (LTBI) for Oscar Health members.

    Policy Summary
    PayerOscar Health
    PolicyTesting for Diagnosis of Active or Latent Tuberculosis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionRequest rapid NAATs and submit appropriate specimens for culture and drug susceptibility testing when clinical suspicion of TB would alter care.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    IGRA >95%reported IGRA specificity for LTBI
    TST ~71–82%reported tuberculin skin test sensitivity
    3 specimensrecommended sputum specimens
    20/100kforeign country TB incidence threshold
    70+evidence references cited

    Coverage Criteria for TB Testing

    IGRA for LTBI screening

    IGRA MEETS CRITERIA when ANY of the following are true:

    IGRA screening indications: a) Individuals who are at risk for infection with Mycobacterium tuberculosis (Mtb). b) Individuals who are unlikely to be infected with Mtb when screening is obliged by law.

    IGRA is intended for detection of latent TB infection and is not adequate for diagnosis of active TB disease; exclude active TB before initiating LTBI treatment.

    Tests that meet criteria for suspected TB infection (active TB)

    For all suspected TB infections, the following MEET CRITERIA (ALL listed):

    Active TB diagnostic tests: a) Acid fast bacilli (AFB) smear/stain. b) Culture and culture-based drug susceptibility testing of Mycobacteria spp. c) Qualitative nucleic acid amplification testing (NAAT) for Mycobacteria spp., M. tuberculosis, and M. avium complex.

    Culture is the diagnostic gold standard; multiple specimens (eg, three sputum specimens) increase diagnostic yield and culture sensitivity.

    Policy Summary
    PayerOscar Health
    PolicyTesting for Diagnosis of Active or Latent Tuberculosis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionRequest rapid NAATs and submit appropriate specimens for culture and drug susceptibility testing when clinical suspicion of TB would alter care.
    SourceLink
    On This Page
    Coverage Criteria for TB TestingApplicable Procedure Codes and Key ThresholdsProvider Responsibilities and Prior Authorization NotesBackground and ScopeDefinitions and AbbreviationsPolicy Revision History

    Molecular-based drug susceptibility testing (DST)

    Molecular-based DST MEETS CRITERIA when ANY one of the following is met:

    Indications for molecular DST: a) Prior TB treatment. b) Born in or lived ≥1 year in a foreign country with TB incidence ≥20 per 100,000 or high primary MDR-TB prevalence (≥2%). c) Contact of an individual with MDR-TB. d) HIV infection.

    Applies to individuals with AFB smear–positive or NAAT-positive respiratory specimens; perform rapid molecular DST for rifampin (± isoniazid) and confirm as indicated.

    Repeat drug susceptibility testing

    Repeat DST MEETS CRITERIA when ANY of the following are present:

    Repeat DST indications: a) Sputum cultures remain positive after 3 months of treatment. b) Bacteriological reversion from negative to positive (culture conversion reversal).

    Repeat resistance testing should be performed to guide changes in therapy and per NIH/CDC recommendations; consider confirmatory molecular and phenotypic testing as indicated.

    Fluid testing in suspected extrapulmonary TB

    Testing of pleural/pericardial/peritoneal/other fluid MEETS CRITERIA when ALL listed:

    Extrapulmonary fluid testing: Cell counts, protein, glucose, and lactate dehydrogenase (LDH) concentrations of cerebrospinal, pleural, peritoneal, pericardial, and other fluids.

    These fluid chemistries meet criteria for individuals with pleural effusion, pericardial effusion, or ascites and suspected TB infection; perform microbiologic testing (AFB smear, NAAT, culture) and histology as indicated.

    LF-LAM in advanced HIV: Urine-based detection of lipoarabinomannan (LAM) MEETS CRITERIA in HIV-infected individuals with signs and symptoms of tuberculosis and CD4 cell counts ≤ 100 cells/microL.CD4 <= 100 cells/microL

    Follow WHO guidance on inpatient/outpatient use and CD4 thresholds for LF-LAM testing.

    Guideline-based diagnostic coverage criteria

    Covered when following guideline-recommended evaluation and use of tests:

    CDC evaluation components: All persons with signs/symptoms of TB disease, or positive TB blood or skin test, should receive a complete medical evaluation consisting of: medical history; physical exam; test for TB infection (TST or IGRA); chest radiograph; bacteriologic examination (sputum smear microscopy, NAAT, culture, and drug susceptibility testing).

    Culture is the gold standard microbiologic test for diagnosis.

    Use of NAATs: NAAT (eg, Xpert MTB/RIF or Xpert Ultra) is recommended as an initial diagnostic test for pulmonary TB and for rapid rifampicin-resistance detection in adults and children with signs/symptoms of pulmonary TB and in specified extrapulmonary specimen types per WHO guidance.

    WHO recommends NAATs as initial tests in many clinical scenarios to enable rapid diagnosis and resistance detection.

    Culture standard: Mycobacterial culture remains the gold standard for diagnosis and is required for confirmation and culture-based drug susceptibility testing; jurisdictions require submission of isolates for confirmation and DST.

    Culture required for definitive microbiologic diagnosis and public health reporting.

    LTBI testing: Either TST or IGRA can be used to test for latent TB infection; WHO notes preventive treatment may be initiated without testing in certain high-risk groups (eg, HIV, young household contacts).

    Testing decisions should consider guideline recommendations and whether a positive result will lead to treatment (test-to-treat principle).

    Guideline-based diagnostic testing recommendations

    Guideline-based testing recommendations (grouped by purpose/population):

    Molecular testing for pulmonary TB (WHO): WHO: Xpert MTB/RIF or Xpert Ultra may be used as the initial test for pulmonary TB in adults when immediate treatment decisions are required and supplementary tests are unavailable or would delay treatment; a single Xpert Ultra may be used rather than two tests as initial testing in adults in the general population.

    Applies to adults and children per WHO conditional/strong recommendations depending on setting.

    Repeated Xpert testing (WHO): WHO: Do not repeat Xpert Ultra in adults with trace positive initial result; repeated testing in children depends on pretest probability and differs between Xpert MTB/RIF and Xpert Ultra recommendations.

    Recommendations vary by age and pretest probability.

    Truenat and Truenat MTB-RIF Dx (WHO): WHO: Truenat MTB or MTB Plus may be used as an initial diagnostic test for pulmonary TB instead of smear microscopy/culture; Truenat MTB-RIF Dx may be used to detect rifampicin resistance as initial test when positive.

    Conditional recommendation; sensitivity may be lower in children.

    Line probe assays (LPAs) (WHO): WHO: For sputum smear–positive specimens or cultured isolates, commercial molecular LPAs may be used instead of phenotypic DST to detect rifampicin and isoniazid resistance; LPAs are not recommended for direct testing of sputum smear–negative specimens, and conventional culture-based DST remains necessary for other agents.

    Accuracy differs by drug and specimen type.

    LF-LAM (WHO): WHO: LF-LAM is strongly recommended to assist diagnosis of active TB in HIV-positive inpatients with signs/symptoms or who are seriously ill, and suggested in outpatients with signs/symptoms and CD4 <100; WHO recommends against LF-LAM use in asymptomatic HIV-positive persons without symptom assessment or with unknown/higher CD4 counts.CD4 thresholds: <200 (inpatient strong), <100 (outpatient suggestion)

    Follow WHO inpatient/outpatient distinctions and CD4-based recommendations.

    AFB smear, culture, NAAT, and molecular DST (ATS/IDSA/CDC and NIH): Guidelines recommend AFB smear microscopy for all suspected pulmonary TB, both liquid and solid mycobacterial cultures for every specimen, NAAT on initial respiratory specimen, and rapid molecular DST for rifampin (± isoniazid) for specified patients; NIH recommends phenotypic DST to first-line drugs for all TB disease patients and confirmatory sequencing when rifampin resistance is detected by commercial NAA.

    Laboratories must validate non–FDA-cleared methods for relevant specimens and submit isolates for public health/genotyping as required.

    Extrapulmonary TB testing (ATS/IDSA/CDC): Perform mycobacterial cultures, NAAT, histology, AFB smear, and fluid studies (cell counts, chemistries, ADA, free IFNγ) on specimens from suspected extrapulmonary TB sites; submit culture isolates for genotyping.

    ADA and IFNγ measurements are suggested by some guideline bodies for certain extrapulmonary sites.

    LTBI testing — modality and age considerations (ATS/IDSA/CDC, AAP): For individuals ≥5 years, IGRA is recommended over TST when testing is warranted (especially with prior BCG or inability to return for TST reading); for healthy children <5 years, TST is suggested over IGRA; for children <2 years, TST preferred (AAP).Age cutoffs: <2 years, <5 years, ≥5 years

    Guidelines discourage universal testing of low-risk individuals and emphasize targeted testing where a positive result would lead to treatment.

    USPSTF screening recommendation: USPSTF (2023) recommends screening asymptomatic adults 18 years or older at increased risk for LTBI, emphasizing that those who screen positive must receive follow-up and treatment; frequency of screening depends on individual risk factors.

    Recommendation applies to asymptomatic adults at increased risk, not to symptomatic patients or children/adolescents.

    Molecular and WGS limitations (IDSA/ASM, TBNET/RESIST-TB): NAATs and molecular tests are adjuncts to culture; a negative NAAT does not rule out TB. WGS provides high discriminatory power but lacks interpretability for many mutations; culture-based DST remains the gold standard for many agents.

    Molecular results may need phenotypic confirmation; reference laboratories recommended for complex DST.

    Covered when targeted clinical indications or guideline criteria are met

    Testing for TB (TST, IGRA, NAAT, culture, DST) is recommended in targeted clinical circumstances:

    Indications for immediate testing: Children who are contacts of confirmed or suspected contagious TB; children with clinical or radiographic findings suggesting TB; children immigrating from countries with endemic infection (including international adoptees); children with significant travel to endemic countries with substantial contact; organ transplant candidates prior to immunosuppression; annual testing for children with HIV.

    Based on AAP recommendations for immediate testing and high-risk pediatric populations.

    When to request rapid NAATs: Request rapid NAATs for M. tuberculosis complex on primary specimens if clinical suspicion of TB exists and (1) the person has HIV, (2) rapid species information would alter care, or (3) a large contact-tracing initiative is being explored. Also request rapid NAAT for rifampin resistance when risk factors for MDR-TB are present (prior TB treatment with poor adherence, contact with MDR-TB case, birth/residence in country with ≥5% MDR among new cases).

    From NICE, ERS/ECDC and other guideline recommendations.

    Specimen testing for suspected pulmonary TB: Adults, adolescents and children capable of producing sputum should have at least two sputum specimens submitted for microscopy and one for rapid molecular testing; send samples for liquid culture and culture-based DST in quality-assured labs; if chest radiograph suggests pulmonary TB, submit sputum for microscopy, rapid molecular tests, culture, species identification, and DST.

    ERS/ECDC and other guidelines recommend multiple specimens to increase sensitivity; three specimens approach ~70% culture sensitivity.

    Use of IGRA vs TST: For children <2 years, TST preferred. For children ≥2 years, either TST or IGRA may be used; IGRA preferred in persons previously vaccinated with BCG to avoid false-positive TST. Consider dual testing in select immunocompromised or high-risk patients; severely immunocompromised adults (eg, HIV with CD4 <200 or post-transplant) may be offered IGRA plus concurrent Mantoux test.

    Guidance from AAP, NTCA/NTSC, NICE and others; testing modality choice should consider age, BCG history, immune status, and whether a positive test will prompt treatment.

    For individuals with known active tuberculosis, interferon-gamma release assays (IGRA) DO NOT MEET CRITERIA. WHO guidance and the policy note that IGRAs are inadequate as rule‑in or rule‑out tests for active TB and should not be used to diagnose active disease; IGRAs are intended for detection of latent TB infection, not active TB. This exclusion ensures that diagnosis of active TB relies on microbiologic and radiographic evaluation (smear, NAAT, culture, and DST) rather than blood‑based immune assays.

    Quantitative nucleic acid amplification testing (NAAT) for Mycobacterium species, including M. tuberculosis and M. avium complex, DOES NOT MEET CRITERIA per the policy. The document lists quantitative NAAT as not meeting criteria due to insufficient evidence that these tests are required and beneficial for diagnosis and management in the contexts reviewed.

    Genotyping of Mycobacterium species is listed in the policy as DOES NOT MEET CRITERIA. While public health and reference laboratories may perform genotyping for epidemiology, the policy states genotyping is not supported as a required diagnostic test in the clinical scenarios covered here because available literature does not establish clinical benefit for routine diagnostic use.

    Testing of adenosine deaminase (ADA) and interferon-gamma (IFNγ) levels in cerebrospinal, pleural, peritoneal, pericardial, and other body fluids for the diagnosis of extrapulmonary TB DOES NOT MEET CRITERIA according to the policy. The policy lists these fluid biomarker measurements among tests that lack sufficient published evidence to confirm they are required and beneficial for diagnosis and treatment decision‑making in the covered clinical contexts.

    Testing of serum protein biomarkers or multi‑analyte biomarker panels for detection or diagnosis of tuberculosis DOES NOT MEET CRITERIA. The policy specifically enumerates these biomarker assays as not meeting criteria because there is inadequate published scientific evidence demonstrating they are required or that they improve patient outcomes.

    The World Health Organization strongly recommends that available commercial serodiagnostic (serological) tests not be used for the diagnosis of pulmonary or extrapulmonary TB. WHO concluded currently available commercial serological assays provide inconsistent and imprecise results and do not improve patient outcomes; therefore their use for TB diagnosis is not recommended.

    WHO guidance notes that commercial line probe assays (LPAs) are appropriate for use on sputum smear‑positive specimens or cultured isolates, but LPAs are not recommended for direct testing of sputum smear‑negative specimens. Regarding the lateral flow urine LAM assay (LF‑LAM), WHO recommends its use to assist diagnosis in specified HIV‑positive populations with symptoms or low CD4 counts, but recommends against LF‑LAM use in asymptomatic HIV‑positive persons without symptom assessment or with higher/unknown CD4 counts.

    The policy discourages universal (routine) testing with either tuberculin skin test (TST) or IGRA because of low yield and a high proportion of false positives; instead the policy promotes targeted testing based on risk factors, exposure, clinical findings, and guideline‑recommended indications (for example, contacts of infectious cases, children with suggestive findings, persons born or residing in high‑prevalence countries, and candidates for immunosuppressive therapy).

    Within the portion of the source provided, there are no additional explicit coverage exclusions beyond those enumerated in the policy text. The listed exclusions (e.g., quantitative NAAT, genotyping, certain fluid biomarkers, commercial serologic tests) represent the tests specifically identified as not meeting criteria in the documented sections.

    Interferon‑gamma release assays (IGRAs) should not be used for diagnosis of active TB disease. WHO and the policy state that IGRAs are inadequate as rule‑in or rule‑out tests for active TB, particularly in contexts such as HIV infection, and that diagnosis of active disease should rely on microbiologic methods (smear, NAAT, culture) and clinical evaluation.

    WHO guidance cautions on use of the lateral flow urine LAM assay (LF‑LAM): it is recommended to assist diagnosis of active TB in HIV‑positive inpatients with symptoms or who are seriously ill and may be suggested in symptomatic outpatients with low CD4 counts, but WHO recommends against using LF‑LAM to assist diagnosis in HIV‑positive persons without symptom assessment or with unknown or higher CD4 counts. The policy mirrors these conditional WHO recommendations and CD4 thresholds.

    The policy reiterates guideline guidance that routine universal screening of low‑risk individuals with TST or IGRA is discouraged due to low diagnostic yield and the potential for many false positives; testing should be targeted to individuals with epidemiologic risk, exposures, clinical signs, or specific guideline‑recommended indications.

    In the provided document excerpts there are no explicit "not medically necessary" statements beyond the exclusions and guideline‑based cautions already documented. The policy lists tests that do not meet criteria and presents guideline‑derived recommendations, but does not include separate additional phrasing labeled "not medically necessary" in these chunks.

    Applicable Procedure Codes and Key Thresholds

    Applicable CPT/HCPCS Procedure Codes (selected list from document)CPT
    81099Unlisted urinalysis procedure.
    82945Glucose, body fluid, other than blood.
    83615Lactate dehydrogenase (LD), (LDH).
    84311Spectrophotometry, analyte not elsewhere specified.
    87206Smear, primary source with interpretation; fluorescent and/or acid-fast stain for bacteria, fungi, parasites, viruses, or cell types.
    87070Culture, bacterial; any other source except urine, blood, or stool, aerobic, with isolation and presumptive identification of isolates.
    87077Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate.
    87150Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.
    87187Susceptibility studies, antimicrobial agent; macrobroth dilution method, each agent.
    87188Susceptibility studies, antimicrobial agent; macrobroth dilution method, each agent.
    1–10 of 15
    1/2
    Foreign country TB incidence threshold
    Foreign country TB incidence threshold>= 20 per 100,000
    Context of useUsed to trigger molecular-based drug susceptibility testing when individual was born in or lived >=1 year in such a country
    Source guidance locationIII. Indications and/or Limitations of Coverage — molecular DST criteria
    High primary MDR-TB prevalence threshold
    High primary MDR-TB prevalence threshold>= 2%
    Context of useUsed to trigger molecular-based drug susceptibility testing when individual was born in or lived >=1 year in such a country
    Source guidance locationIII. Indications and/or Limitations of Coverage — molecular DST criteria
    CD4 cell count threshold for LF-LAM testing in HIV-infected individuals
    CD4 cell count threshold for LF-LAM testing<= 100 cells/microL
    Context of useUrine LAM MEETS CRITERIA in HIV-infected individuals with signs/symptoms of TB and CD4 <= 100 cells/microL
    Referenced evidenceNICE and WHO guidance referenced for urine LAM use in advanced HIV
    Mantoux (TST) positive threshold — induration 5 mm or larger in certain immunocompromised contexts
    Mantoux (TST) positive thresholdInduration of 5 mm or larger
    Context of useConsider active TB assessment if Mantoux >=5 mm in certain immunocompromised adults regardless of BCG history
    Source guidance locationNICE recommendations on Mantoux and follow-up assessment

    Provider Responsibilities and Prior Authorization Notes

    Prior Authorization

    Benefit verification / prior authorization

    Application of these coverage criteria depends on the member’s benefit coverage and any applicable Medicare or Medicaid rules; verify member benefits and prior authorization requirements at time of request and follow state/federal specifications in the ‘Applicable State and Federal Regulations’ section.

    • Verify member benefit coverage and any plan-specific prior authorization requirements before ordering tests.
    • Consult the ‘Applicable State and Federal Regulations’ section for Medicare/Medicaid specifications.
    Prior Authorization

    Prior authorization — none specified

    The policy excerpts provided do not specify payer prior authorization requirements for TB diagnostic tests. Follow standard clinical evaluation and documentation; check member benefits for any plan-specific PA rules.

    • No explicit prior authorization rules are listed in these sections — confirm with payer if needed.
    • Document the diagnostic evaluation components when submitting claims.
    Prior Authorization

    Prior authorization — none specified in this section

    No prior authorization requirements are stated within these policy sections for the tests and procedures described here. Providers should confirm PA needs via the member’s benefit portal or payer communications.

    • Policy text does not define PA for specific TB tests in these chunks.
    • If in doubt, obtain PA per the member’s plan before testing.
    Billing Rule

    Procedure codes — no PA stated

    Procedure and CPT/HCPCS codes listed in the policy are provided as applicable procedure codes; the document does not associate any of these codes with prior authorization requirements.

    • Codes are reference tools for billing — they are not shown as requiring PA in the policy.
    • Confirm any PA needs with the member’s benefits or payer systems prior to submission.
    Prior Authorization

    Prior authorization — no prior authorization requirements stated

    No payer prior authorization requirements are described in the provided sections of this policy. Providers should rely on clinical guidance in the document and verify plan-specific rules separately.

    • Policy sections reviewed contain no stated PA rules.
    • Verify authorization requirements through payer portals as needed.
    Step Therapy

    Test-to-treat expectation for LTBI

    Only test for LTBI in individuals who would benefit from treatment; the decision to test presupposes a decision to treat if results are positive.

    • Do not perform LTBI testing for screening unless the patient is a candidate for and would receive preventive therapy if positive.
    • Document that testing is intended to inform treatment decisions (test-to-treat rationale).
    Step Therapy

    Step therapy — none specified; NAAT recommended when appropriate

    The policy describes no step therapy sequencing or formal step-therapy prior authorization requirements for TB diagnostics; WHO guidance recommends NAAT as the initial diagnostic when clinically appropriate but this is not a payer step-therapy rule.

    • No plan-level step therapy mandates are described in these sections.
    • Follow clinical guidance (e.g., WHO) recommending NAAT (Xpert MTB/RIF or Xpert Ultra) as appropriate for initial diagnosis when indicated.
    Step Therapy

    Step therapy — none specified

    No formal step therapy rules are described in the cited policy sections. Providers should follow clinical recommendations and verify benefit rules for specific plans.

    • Clinical guidance included in the document does not translate to payer step-therapy requirements.
    • Confirm any utilization management rules with the payer.
    Prior Authorization

    Screen for LTBI before starting biologic / immunosuppressive therapy

    When initiating immunosuppressive or biologic therapies (for example TNFα inhibitors), screen for latent TB infection prior to starting therapy and preferably complete LTBI prophylaxis before initiation; document screening and treatment timing.

    • Screen all patients prior to starting TNFα inhibitors or other immunologic therapies.
    • Delay immunologic therapy until LTBI prophylaxis is completed when feasible; if treatment must start earlier, document adherence and tolerance of prophylaxis as noted.
    Step Therapy

    Step therapy — none specified (absence note)

    These sections do not describe step therapy requirements for TB testing or diagnostics.

    • No step therapy requirements are present in the provided chunks.
    • Follow clinical guidelines and plan-specific utilization policies as applicable.
    Documentation Required

    Provider documentation and accurate coding required

    Providers are responsible for submission of accurate documentation of services performed and appropriate coding according to industry-standard coding guidelines; failure to follow coding/billing rules may result in claim denial or recoupment.

    • Code services appropriately per CPT, HCPCS, ICD-10, and other industry standards when submitting claims.
    • Maintain accurate clinical documentation to support billed services and medical necessity.
    Documentation Required

    Required evaluation components to document

    Documentation of the TB evaluation should include medical history, physical examination, TB infection test results (TST or IGRA), chest radiograph findings, and bacteriologic testing (smear, NAAT, culture, and DST) when evaluating for TB disease.

    • Include results of TST or IGRA and an assessment that active TB was excluded prior to LTBI treatment.
    • Record chest radiograph findings and bacteriologic test orders/results (smear, NAAT, culture, DST) in the medical record.
    Documentation Required

    Culture submission and drug susceptibility testing documentation

    For patients with culture-positive TB, submit one culture isolate from each culture-positive patient to a regional genotyping laboratory and perform/document phenotypic DST for first-line drugs; perform rapid molecular DST on initial isolates and confirm rifampin resistance by sequencing or phenotypic DST when indicated.

    • Submit culture isolates for genotyping per guidance.
    • Document phenotypic DST for first-line drugs for all TB disease patients and perform confirmatory testing when commercial NAA indicates rifampin resistance.
    Documentation Required

    Specimen submission and rapid NAAT documentation

    Request rapid diagnostic NAATs for M. tuberculosis complex on primary specimens when clinical suspicion exists and when results would alter management (for example, HIV, need for rapid species info, or contact tracing); for suspected pulmonary TB, obtain at least two sputum specimens for microscopy and one for rapid molecular testing and send samples for culture and DST as indicated.

    • Order NAAT on primary specimens when rapid species or resistance information would change care.
    • Collect at least two sputum specimens for microscopy plus one for NAAT in patients able to expectorate; send specimens for liquid culture and culture-based DST in quality-assured labs.
    Note

    Evidence references (no additional documentation requirements)

    This section of the document contains evidence references and does not add additional provider documentation requirements beyond those stated elsewhere in the policy.

    • Use referenced guidance and studies to support clinical decisions as needed.
    • No new documentation actions are specified in the evidence references section.
    Denial Risk

    Claims denial risk for improper coding/billing

    Claims may be denied or recouped if appropriate coding/billing guidelines or current reimbursement policies are not followed; ensure accurate coding and adherence to reimbursement rules when submitting claims.

    • Noncompliance with coding and billing guidance (e.g., CCI edits, CMS guidance) can lead to claim denial or recoupment.
    • Ensure documentation supports billed services and medical necessity.
    Denial Risk

    Incomplete evaluation may risk inappropriate care or denials

    Failure to perform a complete medical evaluation when indicated — including medical history, physical exam, TB infection testing, chest radiograph, and bacteriologic testing — could result in inappropriate management and may affect coverage/authorization.

    • Perform and document the five CDC components of TB evaluation when clinically indicated.
    • Incomplete evaluation may lead to inappropriate treatment decisions or claims issues.
    Denial Risk

    Exclude active TB before starting LTBI treatment

    Before initiating treatment for LTBI, clinicians must exclude active TB using symptom assessment, chest imaging, and bacteriologic testing as indicated; testing that does not exclude active TB prior to LTBI treatment may be inappropriate.

    • Assess for symptoms suggestive of TB, obtain chest radiograph, and sample for microbiology if radiographic signs of active TB are present.
    • Document explicit exclusion of active TB in the medical record before starting LTBI therapy.
    Denial Risk

    Government policy precedence — check LCDs/NCDs/state rules

    If this policy conflicts with any applicable government policy (e.g., LCDs, NCDs, or state Medicaid), the government policy takes precedence; follow government requirements to avoid denials.

    • Check for applicable Medicare/Medicaid coverage rules and local coverage determinations when they differ from this policy.
    • Adhere to government policy where conflicts exist to guide coverage decisions.
    Note

    Authorization/denial criteria not specified in these sections

    No explicit authorization or denial criteria are presented in the provided document sections.

    • Policy sections reviewed do not define specific authorization or denial rules beyond general statements.
    • For authorization decisions, verify plan-specific criteria and consult payer resources as needed.

    Background and Scope

    Mycobacterium tuberculosis infection can range from asymptomatic latent infection to active disease, most commonly pulmonary with symptoms such as prolonged cough, fever, night sweats, and weight loss. The policy reiterates that culture is the diagnostic gold standard for TB, NAATs (e.g., Xpert MTB/RIF, Xpert Ultra) provide more rapid and sensitive detection than smear, and IGRAs are intended to detect latent TB infection (LTBI) rather than diagnose active disease. Identification and treatment of LTBI remain important TB control strategies because latent infection can reactivate to cause active disease.

    Definitions and Abbreviations

    IGRA — Interferon gamma release assay definition
    DefinitionInterferon gamma release assay (IGRA): blood tests measuring T-cell release of interferon-gamma after stimulation by M. tuberculosis antigens to detect latent TB infection
    Intended useUsed to diagnose or screen for latent TB infection (not for active TB disease)
    Clinical preferencePreferred in many non–U.S.-born persons (BCG vaccinated) and in persons unlikely to return for TST reading
    AFB — Acid fast bacilli smear/stain definition
    DefinitionAFB: Acid fast bacilli smear/stain — microscopic examination of stained sputum to rapidly detect mycobacteria
    Performance noteFastest and cheapest diagnostic tool but limited sensitivity in extrapulmonary disease and in persons with HIV; fluorescence/LED microscopy improves sensitivity
    Role in algorithmUsed as initial rapid test alongside NAAT and culture for suspected active TB
    NAAT / Xpert MTB/RIF / Xpert Ultra — NAAT definitions and notes
    DefinitionNAAT (including Xpert MTB/RIF and Xpert Ultra): nucleic acid amplification tests that detect M. tuberculosis complex genetic material and often assess rifampin resistance
    Performance noteMore sensitive than smear and faster than culture; >95% PPV in AFB smear–positive specimens and detects 50–80% of smear-negative specimens
    Guidance noteRecommended by WHO as initial diagnostic test in many clinical scenarios; does not replace culture for gold-standard confirmation and DST
    LTBI (latent TB infection) — definition
    DefinitionLTBI (latent TB infection): state in which a person has a positive TST or IGRA but medical evaluation does not indicate active TB disease; bacteria are contained and person is not infectious
    Clinical implicationIndividuals with LTBI are asymptomatic but may benefit from preventive treatment to reduce risk of reactivation
    Testing noteTST or IGRA can be used to diagnose LTBI; no gold standard exists and both require competent immune response
    Acid fast bacilli (AFB) smear — definition and sensitivity notes
    DefinitionAcid fast bacilli (AFB) smear: microscopic examination of stained sputum to detect mycobacteria rapidly
    Sensitivity notesLimited sensitivity compared with culture; sensitivity increased by fluorescence/LED microscopy (~10%), specimen concentration, and multiple specimens
    Operational noteOften used as the fastest screening test while culture and NAAT results are pending
    LTBI — additional definition
    Additional LTBI definitionInfection with M. tuberculosis in which bacteria are alive but contained by the immune system; persons are asymptomatic, not infectious, and usually test positive on TST or IGRA
    Public health noteIdentification and treatment of LTBI are important TB control strategies to prevent reactivation
    Testing limitationsTST and IGRA are imperfect predictors of progression to active disease; choose test based on age, BCG history, and clinical context
    Active TB (TB disease) — definition
    DefinitionActive TB (TB disease): illness in which TB bacteria are multiplying and attacking body tissue (usually lungs); may be symptomatic and infectious
    Diagnostic standardCulture is the gold standard for microbiologic diagnosis; NAAT and AFB smear are adjuncts for rapid detection
    Clinical featuresSymptoms can include prolonged cough, fever, night sweats, and weight loss; evaluate with clinical assessment, chest radiograph, and bacteriologic testing
    WGS — Whole genome sequencing definition and limitations
    DefinitionWhole genome sequencing (WGS): provides complete bacterial genome sequence information
    LimitationsCurrently limited clinical interpretability for many mutations due to incomplete correlation with phenotypic DST and treatment outcomes
    RoleUseful for high-resolution epidemiology and resistance investigation but phenotypic DST remains necessary for many clinical decisions
    Two-step TST — definition
    DefinitionTwo-step TST: initial tuberculin skin test followed by a second test 1–3 weeks later to detect boosted reactions and establish a baseline for serial testing
    Use caseRecommended when serial TST testing is expected (e.g., health care personnel) to distinguish boosting from new infection
    Comparison noteIGRAs do not cause boosting and therefore do not require two-step testing for serial surveillance
    NAAT / nucleic acid amplification tests — referenced guidance and studies
    DefinitionNAAT / nucleic acid amplification tests: molecular assays for rapid detection of M. tuberculosis complex and some resistance mutations
    Guidance referencesCDC updated guidelines and WHO/CDC guidance support NAAT use as initial diagnostic tests in many contexts; see listed evidence references
    Performance summaryMore sensitive than smear, less sensitive than culture; rapid molecular DST may indicate rifampin resistance but requires confirmation in some settings
    Urine lipoarabinomannan (LAM) testing — definition and references
    DefinitionUrine lipoarabinomannan (LAM) testing: lateral-flow assays detecting mycobacterial cell wall glycolipid LAM in urine to assist diagnosis of active TB in HIV-positive individuals
    Indication and thresholdMEETS CRITERIA in HIV-infected individuals with signs/symptoms of TB and CD4 <= 100 cells/microL (policy) with additional WHO/NICE guidance for CD4-based use
    Evidence baseDiagnostic accuracy studies and systematic reviews (Cochrane) and randomized trials (e.g., STAMP) cited in evidence references

    Policy Revision History